Epigenomics licenses marker to Predictive Bio

Epigenomics, a German cancer molecular diagnostics company, has entered into a non-exclusive licensing agreement for its  GSTP1 DNA methylation  biomarker with USA-based Predictive Biosciences, a privately-held cancer  molecular diagnostics company.

Under the agreement, Predictive Bio has obtained rights to uses of  mGSTP1 to establish and commercialize a molecular-based,  laboratory-developed test that can help urologists and pathologists  better diagnose and manage prostate cancer. Financial terms were not  disclosed.

"We are pleased that Predictive Biosciences is adding DNA methylation to  its menu of molecular diagnostic tests using our technology and  biomarker. They share our goal to develop cancer tests that will help  physicians achieve improved health outcomes for their patients through  better diagnosis of prostate cancer," said Geert Nygaard, chief  executive of Epigenomics.